LAG3 and plasma cell myeloma: Deletion of TIM-3, LAG-3, and 2B4 genes by CRISPR-Cas9 led to superior functionality and resistance to exhaustion of transgenic TCR NY-ESO-1-specific T cells in preclinical myeloma models.